A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. (Q34632661)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

multicenter clinical trial

0 references

juvenile rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Pierre Quartier

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Brigitte Bader-Meunier

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Nico M Wulffraat

3

object named as

Nico Wulffraat

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Alberto Martini

13

object named as

Alberto Martini

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Abhijit Chakraborty

12

object named as

Abhijit Chakraborty

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Patricia Woo

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Richard Mouy

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sebastiaan J Vastert

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Emanuele Noseda

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Daniele D'Ambrosio

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jean Lecot

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Andrea Chioato

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Paediatric Rheumatology International Clinical Trials Organisation

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Nicolino Ruperto

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 February 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Arthritis and Rheumatism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

64

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

557-567

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Outcome following onset of juvenile idiopathic inflammatory arthritis: II. predictors of outcome in juvenile arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

The German etanercept registry for treatment of juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Inflammasomes and rheumatic diseases: evolving concepts

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Physiologic role of interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Blocking IL-1 in systemic inflammation

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

The emerging role of interleukin-1β in autoinflammatory diseases

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Use of canakinumab in the cryopyrin-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO).

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Repeated events survival models: the conditional frailty model.

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

1 reference

https://api.crossref.org/works/10.1002%2FART.33342

21 January 2018

Identifiers

10.1002/ART.33342

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21953497%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34632661&oldid=2060904778"